Stock Events

Stock Events

Dyne Therapeutics 

$16.30
30
-$1.62-9.04% 09:01 Today

Statistics

Day High
17.95
Day Low
17.91
52W High
27.31
52W Low
14
Volume
64,849
Avg. Volume
-
Mkt Cap
3.36B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-1.08
-0.96
-0.85
-0.73
Expected EPS
-0.907278
Actual EPS
-1.06

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-446.21MNet Income

Analyst Ratings

$31.50Average Price Target
The highest estimate is ⁦47.00⁩.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
90%
Hold
0%
Sell
10%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DYN. It's not an investment recommendation.
AMD
8
AMD
NVIDIA
7
NVDA
Palantir Technologies
7
PLTR
Broadcom
7
AVGO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Dyne's focus on muscle diseases.
Ionis Pharmaceuticals
IONS
Mkt Cap6.55B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the same space as Dyne with a focus on genetic and rare diseases.
PTC Therapeutics
PTCT
Mkt Cap5.47B
PTC Therapeutics operates in the field of genetic disorders, including Duchenne muscular dystrophy, which overlaps with Dyne's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap735.51M
Solid Biosciences is focused on treatments for Duchenne muscular dystrophy, directly competing with Dyne's muscle disease programs.
Wave Life Sciences
WVE
Mkt Cap1.2B
Wave Life Sciences is involved in designing, discovering, and developing RNA therapeutics for genetically defined diseases, competing in the same niche as Dyne.
Ultragenyx Pharmaceutical
RARE
Mkt Cap1.57B
Ultragenyx Pharmaceutical focuses on rare and ultra-rare diseases, including genetic disorders, which is a direct competition to Dyne's focus areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.85B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including genetic disorders.
Alnylam Pharmaceuticals
ALNY
Mkt Cap20.89B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, targeting genetic diseases, which puts it in competition with Dyne.
Editas Medicine
EDIT
Mkt Cap394.7M
Editas Medicine works on gene editing technologies, including CRISPR, to treat genetic diseases, offering an alternative approach to Dyne's RNA-focused therapies.

About

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Show More
CEO
John G. Cox
Employees
258
Country
United States
ISIN
US26818M1080

Listings

XNAS
US
DYN
BOATS
BOATS
DYN.BOATS

0 Comments

Share your thoughts

FAQs

What is Dyne Therapeutics stock price today?▼
The current price of DYN is $16.30 USD — it has decreased by -9.04% in the past 24 hours. Watch Dyne Therapeutics stock price performance more closely on the chart.
What is Dyne Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Dyne Therapeutics stocks are traded under the ticker DYN.
Is Dyne Therapeutics stock price growing?▼
DYN stock has fallen by -3.34% compared to the previous week, the month change is a +7.69% rise, over the last year Dyne Therapeutics has showed a -8.9% decrease.
What is Dyne Therapeutics market cap?▼
Today Dyne Therapeutics has the market capitalization of 3.36B
When is the next Dyne Therapeutics earnings date?▼
Dyne Therapeutics is going to release the next earnings report on March 4, 2027.
What were Dyne Therapeutics earnings last quarter?▼
DYN earnings for the last quarter are -1.06 USD per share, whereas the estimation was -0.91 USD resulting in a -16.83% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dyne Therapeutics revenue for the last year?▼
Dyne Therapeutics revenue for the last year amounts to 0 USD.
What is Dyne Therapeutics net income for the last year?▼
DYN net income for the last year is -446.21M USD.
How many employees does Dyne Therapeutics have?▼
As of November 11, 2026, the company has 258 employees.
In which sector is Dyne Therapeutics located?▼
Dyne Therapeutics operates in the Health & Wellness sector.
When did Dyne Therapeutics complete a stock split?▼
The last stock split for Dyne Therapeutics was on August 22, 2000 with a ratio of 2:1.
Where is Dyne Therapeutics headquartered?▼
Dyne Therapeutics is headquartered in WALTHAM, United States.